Venlon Enterpris (524038)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROE of 17.05%, though it likely reflects trailing earnings rather than current conditions, shows some past profitability.
• Tiny market cap of ₹29 Cr means even a small absolute recovery in operations could have a significant effect on per-share value.
• Share price of ₹5.56 is near the lower end of the 52-week range, so much pessimism may already be priced in.
• Commodity chemicals offer potential operating leverage if industrial demand recovers.

Concerns

• Latest quarter had only ₹1 Cr sales and a ₹1 Cr net loss; sales growth is -57.24% and profit growth -59.09%.
• ROCE is deeply negative at -38.61%, and the Piotroski F-Score of 2/9 indicates weak fundamentals.
• Book value, debt/equity, and promoter holding are unavailable, making a balance-sheet safety check impossible.
• Zero dividend and zero earnings give shareholders no current return while waiting for a turnaround.

AI Analysis

At ₹5.56, Venlon Enterpris has a market capitalisation of only ₹29 crore. Graham would remind me that small size is not a substitute for safety, and Buffett would ask how durable the franchise is. This is a commodity chemicals business, so pricing power is limited. The figures paint a deeply troubled picture: sales have fallen 57.24%, profit growth is down 59.09%, and the latest quarter shows just ₹1 crore of sales against a ₹1 crore net loss. ROCE is a severe negative 38.61%, meaning the company is destroying value on its existing capital base. The Piotroski F-Score of 2 out of 9 supports this: this is not a financially healthy enterprise. The reported ROE of 17.05% seems inconsistent with the current loss-making quarter; it likely reflects an earlier, better period or a very thin equity base. I cannot rely on it. P/E is meaningless at zero earnings. Worse, book value, debt-to-equity and promoter holding are all unavailable, so I cannot compute a Graham-style margin of safety. There is zero dividend to reward patience. The price is near the lower end of its 52-week range, which means Mr. Market is already pessimistic. But pessimism alone is not an investment thesis. A commodity chemical player at this stage needs evidence of a demand recovery, improved capacity utilisation, and positive operating cash flow. Without those, any apparent cheapness is a value trap, not a bargain. I would keep Venlon on a watchlist, not in my portfolio. Valuation cannot rescue a cash-burning business with no moat, negative returns on capital, and insufficient data. Let the numbers stabilise first; then I can consider whether a purchase offers the margin of safety Graham demanded.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer